Investigational drug · Phase 3
SHR-3167
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetes Mellitus, Type 2, Type 2 Diabetes, Type 2 Diabetes Mellitus.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
9
Any phase or sponsor naming "SHR-3167"
First trial start
2025
Jan 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-3167", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetes Mellitus, Type 2
- Type 2 Diabetes
- Type 2 Diabetes Mellitus
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-3167" as an intervention, largest first.
- A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal InsulinPivotal-lookingNot yet recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07913061 · 680 participants (planned) · Start Nov 2026 · Primary completion Jan 2028
Drug: SHR-3167; insulin degludec · For: Diabetes Mellitus, Type 2
Sites: Shenzhen, China; Shanghai, China
- Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 DiabetesPivotal-lookingNot yet recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07920939 · 450 participants (planned) · Start Nov 2026 · Primary completion Oct 2027
Drug: SHR-3167 Injection; Insulin glargine (IGlar) · For: Type 2 Diabetes
Sites: Nanjing, China; Shanghai, China
- Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes SubjectsPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06688123 · 275 participants · Start Jan 8, 2025 · Primary completion Apr 22, 2026
Drug: SHR-3167; SHR-3167 and 1 more · For: Type 2 Diabetes
Sites: Nanjing, China; Shanghai, China
- A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic DrugsPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07018453 · 173 participants · Start Jul 16, 2025 · Primary completion Feb 2026
Drug: SHR-3167; Insulin Degludec · For: Type 2 Diabetes Mellitus
Sites: Chongqing, China; Shanghai, China
- A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic AgentsPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07472725 · 102 participants · Start Apr 11, 2026 · Primary completion Dec 2026
Drug: SHR-3167 Injection; SHR-3167 Injection Placebo · For: Diabetes Mellitus, Type 2
Sites: Shenzhen, China; Nanjing, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07489482 · 60 participants (planned) · Start Apr 2, 2026 · Primary completion Dec 2026
Drug: SHR-3167 Injection · For: Diabetes Mellitus
Sites: Changsha, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07032688 · 55 participants (planned) · Start Aug 11, 2025 · Primary completion Mar 2027
Drug: SHR-3167 Injection; Insulin Degludec Injection · For: Type 2 Diabetes
Sites: Chengdu, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05996380 · 52 participants (planned) · Start Jun 9, 2023 · Primary completion Jan 25, 2024
Drug: SHR-3167; SHR-3167 Placebo · For: T2DM
Sites: Nanjing, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07588906 · 24 participants · Start Feb 26, 2024 · Primary completion Jul 12, 2024
Drug: SHR-3167 injection;glargine insulin · For: Healthy Subjects
Sites: Chongqing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabetes Mellitus, Type 2
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.